D. Boral Capital Reaffirms Buy Rating for Hoth Therapeutics (NASDAQ:HOTH)

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They currently have a $5.00 price target on the stock. D. Boral Capital’s target price points to a potential upside of 397.51% from the stock’s current price.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Hoth Therapeutics in a report on Thursday, January 23rd.

Hoth Therapeutics Stock Performance

HOTH traded up $0.14 during trading hours on Tuesday, reaching $1.01. The company’s stock had a trading volume of 3,701,825 shares, compared to its average volume of 12,814,855. The firm has a market cap of $6.94 million, a PE ratio of -0.76 and a beta of 0.80. The company’s 50-day moving average is $1.19 and its 200-day moving average is $0.98. Hoth Therapeutics has a 52 week low of $0.58 and a 52 week high of $3.80.

Hedge Funds Weigh In On Hoth Therapeutics

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned about 0.47% of Hoth Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 7.08% of the stock is currently owned by institutional investors and hedge funds.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.